ACC/AHA 2026 Cholesterol Guideline: LDL Targets Changed, Lp(a) is Now a Routine Measurement, and the PREVENT Risk Score

Quick Clinician Summary — 5 Critical Changes

• LDL targets are back:
  • <55 mg/dL (very high risk)
  • <70 mg/dL (high risk)
  • <100 mg/dL (primary prevention)
• Lp(a) is now a routine measurement recommendation — at least once in a lifetime for everyone.
• PREVENT-ASCVD risk calculator has replaced the old PCE.
• Combination therapy (statin + ezetimibe) is moved to an earlier stage.
• Initiate treatment in young adults if LDL >= 160 mg/dL.
• Reduce lifetime exposure to atherogenic lipoproteins.
• Initiate screening and treatment at younger ages.
• Therefore, lifestyle interventions must begin very early.

Introduction: A Comprehensive Update Replacing the 2018 Guideline 

The ACC (American College of Cardiology) and AHA (American Heart Association) published the new ‘Guideline on the Management of Dyslipidemia’ in 2026. Replacing the 2018 cholesterol guideline, this document approaches dyslipidemia assessment, treatment, and monitoring within a holistic framework.

The scope of the guideline is not limited solely to LDL cholesterol; triglycerides, Lp(a), and other lipid disorders are also detailed. The most important message for clinical practice is this: early screening, aggressive targets, and combination therapy are now built on a stronger evidence base.

1. Core Philosophy: ‘Lower LDL Earlier, for Longer’

The foundational approach of the new guideline is built on three principles:

1. Reduce lifetime exposure to atherogenic lipoproteins
2. Initiate screening and treatment at younger ages
3. Lower LDL to more aggressive targets and maintain that target

Therefore, lifestyle interventions must now begin very early, long before cardiovascular disease appears. Atherosclerosis is not treated once established; it is only slowed down or halted. Prevention is key.

2. New Model in Risk Assessment: PREVENT-ASCVD

The guideline abandons the old Pooled Cohort Equations (PCE) risk calculator in favor of the PREVENT-ASCVD risk calculator. This change is highly significant in practice:

• PREVENT takes diabetes, chronic kidney disease (CKD), and cardiovascular biomarkers into account.
• It offers a more valuable estimation across broader patient populations.
• When used alongside the CAC (Coronary Artery Calcium) score, it can facilitate decision-making in borderline cases.

Practical Note: You can access the PREVENT-ASCVD calculator via the official ACC website. Consider using the CAC score as a supportive tool for borderline risk patients.

3. LDL Targets Brought Back — The Biggest Difference from 2018

The 2018 guideline adopted an approach emphasizing percentage reduction. The 2026 guideline has clearly redefined absolute target LDL levels. This means major practical convenience for clinicians.

Secondary Prevention (Patients with an ASCVD Diagnosis)

Primary Prevention (Patients without an ASCVD Diagnosis)

What Does This Mean in Practice? If you previously set a target of 70 mg/dL for your patients with an ASCVD diagnosis, you may need to revise this plan to 55 mg/dL. The addition of ezetimibe has now been made an earlier step.

4. Lipoprotein(a) Measurement is Now a Routine Recommendation

One of the most striking innovations of the ACC/AHA 2026 is that Lp(a) screening has become a universal recommendation.

Why is it Important?

• Lp(a) is an inherited cardiovascular risk factor that does not respond to statin therapy.
• >= 50 mg/dL (approx. 125 nmol/L) -> Independently increases ASCVD risk.
• >= 100 mg/dL -> Risk increases approximately 2-fold.
• If high Lp(a) is present, a more aggressive LDL lowering strategy is recommended.

Recommendation: Lp(a) measurement at least once in a lifetime for every individual is now a Class I recommendation level. ESC 2025 also considers an Lp(a) level >50 mg/dL as a marker that refines risk stratification.

Clinical Point: Consider ordering an Lp(a) measurement from the very first visit for patients with a family history of premature cardiovascular disease, those unable to reach their LDL target despite statins, or those with an unexplained high-risk profile.

5. Early Treatment in Young Adults

The guideline defines new thresholds for young adults for early cardiovascular intervention:

The goal can be summarized in one sentence: Intervene before atherosclerosis begins.

6. Treatment Steps: Lifestyle and Medication

6.1 Lifestyle Interventions (Always the First Step)

• Mediterranean diet (the strongest evidence-based nutritional model)
• Weight control — abdominal obesity increases the risk multiplier
• Regular physical activity (at least 150 min of moderate intensity per week)
• Smoking cessation — increases HDL, reduces inflammation

6.2 Medical Therapy Algorithm

What Does This Mean in Practice? 

Combination therapy is no longer repositioned as a ‘last resort’, but rather ‘add early if the target is not met’. Especially in very high-risk patients, if the target is not reached at the first check-up, ezetimibe should be added without delay.

7. Triglyceride Management

Statins continue to be the primary therapy in triglyceride management. However, threshold values for severe elevations have been clarified:

8. Special Patient Groups

In the patient groups below, the risk should be considered high independent of the LDL level, and lipid-lowering therapy should be considered in primary prevention:

9. Practical Algorithm for the Outpatient Clinic

Aligned with the official messages of ACC/AHA 2026 and the aggressive target approach of the ESC, this algorithm can be used in routine dyslipidemia outpatient visits:

Step 1 — Basic Panel for Every Patient

• Full lipid panel (fasting or non-fasting measurement)
• Liver functions (ALT/AST)
• Creatinine / eGFR
• HbA1c or glucose status
• TSH (when necessary — hypothyroidism can be a cause of dyslipidemia)
• Lp(a) — at least once in a lifetime ACC/AHA 2026 explicitly recommends that Lp(a) be measured at least once. ESC 2025 also accepts an Lp(a) level >50 mg/dL as a marker refining risk stratification.

Step 2 — Determine the Risk

• Calculate the 10-year risk with the PREVENT-ASCVD calculator
• Refine the risk with a CAC score in borderline cases
• Familial Hyperlipidemia? Family history? Lp(a)? -> Incorporate risk multipliers

Step 3 — Determine the Target

Step 4 — Stepwise Treatment

• Lifestyle is always foundational
• Start with a statin -> add ezetimibe early if you don’t reach the target
• If reduction is insufficient, evaluate a PCSK9 inhibitor or inclisiran

10. Overall Assessment: America Approaches Europe

The ACC/AHA 2026 lipid guideline has brought the American cardiology approach significantly closer to the ESC (European Society of Cardiology) standards. The practical differences between the two guidelines have diminished:

Frequently Asked Questions (FAQ)

How is the ACC/AHA 2026 cholesterol guideline different from 2018? 

The 2026 guideline abandoned the 2018 guideline’s emphasis on percentage reduction and defined clear LDL targets (<55 mg/dL for very high risk, <70 mg/dL for high risk). In addition, it made Lp(a) measurement routine and replaced the old PCE with the PREVENT-ASCVD risk calculator.

What should your LDL cholesterol target be? 

Depending on your risk group: <55 mg/dL if there is very high risk or an ASCVD diagnosis; <70 mg/dL if high risk; <100 mg/dL if low-intermediate risk in primary prevention. These targets are determined according to the ACC/AHA 2026 guideline.

Why should Lp(a) be measured? 

Lp(a) is an inherited cardiovascular risk factor that does not respond to statins. Levels >= 50 mg/dL increase ASCVD risk, while levels >= 100 mg/dL increase the risk approximately 2-fold. The ACC/AHA 2026 recommends measuring Lp(a) at least once in a lifetime for everyone.

When are PCSK9 inhibitors used? 

When the LDL target cannot be reached despite a combination of a high-intensity statin and ezetimibe, PCSK9 inhibitors (evolocumab, alirocumab) come into play. Early use should be considered especially in very high-risk patients and those with familial hypercholesterolemia.

How is the PREVENT-ASCVD risk calculator used? 

PREVENT-ASCVD is available for free on the official ACC website. When age, gender, systolic BP, total cholesterol, HDL, diabetes, and CKD status are entered, the 10-year cardiovascular risk is calculated. It is recommended to refine the outcome with a CAC score for borderline risk patients.

References

1. ACC/AHA 2026 Guideline on the Management of Dyslipidemia. American College of Cardiology / American Heart Association. 2026.
2. ESC/EAS 2025 Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2025.
3. Jones DW, Ferdinand KC, Taler SJ et al. Circulation 2025;152:e114-e218 — 2025 Hypertension Guideline.
4. Grundy SM et al. 2018 ACC/AHA Cholesterol Guideline. Circulation. 2019;139:e1082-e1143.

This article is for informational purposes only and does not replace medical advice. Always consult a physician for a definitive diagnosis and treatment.